ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
28 hedge funds and large institutions have $3.41M invested in ImmunoCellular Therapeutics, Ltd. in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
28% less capital invested
Capital invested by funds: $4.76M → $3.41M (-$1.35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$113K |
| 2 |
Renaissance Technologies
New York
|
+$93.3K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$8.12K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.35K |
| 5 |
LPL Financial
San Diego,
California
|
+$4.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
-$945K |
| 2 |
FAAS
First Allied Advisory Services
San Diego,
California
|
-$19K |
| 3 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$5K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.04K |
IMUC Hedge Fund Activity: Q4 2015 in Review
28 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q4 2015, worth a combined $3.41M — down 28% from $4.76M a quarter earlier.
Fund positioning in IMUC was balanced in Q4 2015: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $113K. The largest seller was Bailard, exiting entirely with an estimated $945K sold.
- 28 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $3.41M of ImmunoCellular Therapeutics, Ltd. stock for Q4 2015, down 28% quarter-over-quarter.
- 6 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q4 2015 and 6 closed out, a net change of 0 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q4 2015 was Sabby Management, an estimated $113K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q4 2015 was Bailard, an estimated $945K sold.
Based on aggregated 13F filings for Q4 2015.